Skip to main content
letter
. 2018 Aug 6;1:2. Originally published 2018 Apr 18. [Version 2] doi: 10.12688/aasopenres.12841.2

Table 1. Road blocks to schistosome vaccine development and how controlled human infection models for schistosomiasis can help.

(CHI-S) - Controlled human infection model for Schistosoma mansoni.

Road blocks How CHI-S can help
Vaccine candidates:
Several vaccine candidates are available; but
• there are limited resources to take candidates
forward
• the focal and dynamic epidemiology of
schistosomiasis may make efficacy studies
difficult
• the requirement for pretreatment of subjects
before vaccine testing can influence epidemiology
and complicate the efficacy evaluation
graphic file with name aasopenres-1-13967-g0001.jpg  ✓   CHI-S quickly identifies candidates most likely to induce
protection
 ✓   CHI-S can be performed in populations with defined
pre-exposure
Animal models:
Suitability of various animals for predicting responses
to, and efficacy of, vaccine candidates in humans not
known
graphic file with name aasopenres-1-13967-g0001.jpg  ✓   CHI-S provides direct evidence of responses in humans
Immunological road-blocks:
•   Schistosomes induce regulatory responses which
could impair vaccine immunogenicity
•   Schistosomes induce Th2 responses and IgE with
accompanying risk of allergic phenomena
•   Th1 responses involved in protection not known in
humans
•   Correlates of protection not known
graphic file with name aasopenres-1-13967-g0001.jpg  ✓   CHI-S describes evolution of immune responses
following infection
 ✓   Combined with a model “vaccine” (such as irradiated
cercariae, predicted to be effective) CHI-S identifies
protective Th1 responses and correlates of protection